Active, not recruitingPhase 2NCT04919512
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Studying Muscular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- TAR-200(drug)
- Enrollment
- 163 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
- UAMS Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
- Arkansas Urology, Little Rock, Arkansas, United States
- City of Hope, Duarte, California, United States
- Genesis Research, San Diego, California, United States
- Colorodo Urology- St. Anthony Hospital, Golden, Colorado, United States
- University of Florida Health Jacksonville, Jacksonville, Florida, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Baptist Hospital of Miami, Miami, Florida, United States
- Winship Cancer Institute Emory University, Atlanta, Georgia, United States
- DuPage Medical Group, Lisle, Illinois, United States
- Urology of Indiana, Indianapolis, Indiana, United States
- First Urology, Jeffersonville, Indiana, United States
- University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04919512 on ClinicalTrials.govOther trials for Muscular tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07144319Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyPhotocure
- RECRUITINGPHASE2NCT07475403Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderAstellas Pharma Global Development, Inc.
- RECRUITINGNANCT07431788The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionErkan Gol
- RECRUITINGNANCT07339761Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyUniversity of Aarhus
- RECRUITINGPHASE2NCT07363057A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer SurvivorsGI Innovation, Inc.
- RECRUITINGPHASE3NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGNANCT07001670Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection SurgeryIstanbul University